Welcome to our dedicated page for Cybin news (Ticker: CYBN), a resource for investors and traders seeking the latest updates and insights on Cybin stock.
The CYBN news page on Stock Titan provides an archive of news releases and updates related to Cybin Inc., a Phase 3 clinical-stage neuropsychiatry and pharmaceutical company focused on developing next-generation treatment options for mental health conditions. These news items come directly from the company’s public communications and are also referenced in its Form 6-K filings with the U.S. Securities and Exchange Commission.
Readers can find coverage of Cybin’s clinical development programs, including updates on its lead candidates CYB003, a proprietary deuterated psilocin analog in Phase 3 studies for adjunctive treatment of major depressive disorder, and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. News releases describe milestones such as trial enrollment progress, regulatory approvals to initiate studies in various countries, and participation in healthcare and investor conferences.
The news feed also includes information on Cybin’s capital markets activity, such as registered direct offerings of common shares and pre-funded warrants, the establishment and use of an at-the-market equity program, and the company’s stated intentions for the use of proceeds, including repayment of convertible debentures and funding of its clinical programs. Corporate updates, including plans to transfer its U.S. stock exchange listing from the NYSE American to the Nasdaq Global Market and the associated change in ticker symbol from CYBN to HELP, are documented in detail.
Because Cybin files many of these news releases as exhibits to Form 6-K, the CYBN news page serves as a convenient way to follow the narrative of its clinical progress, financing decisions, and listing changes over time. Investors and researchers can use this archive to review how the company describes its strategy in neuropsychiatry, its geographic operations in Canada, the United States, the United Kingdom, and Ireland, and its stated commitment to rigorous scientific research and regulatory compliance for its investigational compounds.
Cybin, a biotechnology company focused on psychedelic therapeutics, has announced a new partnership with Catalent, the leader in drug delivery technologies. The agreement allows Cybin to utilize Catalent’s proprietary Zydis® orally disintegrating tablet (ODT) technology for its novel drug CYB003, aimed at treating resistant psychiatric disorders. This innovative delivery method promises improved pharmacokinetics by enabling pre-gastric absorption. The project begins in April 2021 with feasibility studies on various ODT formulations.
Cybin has successfully completed its 20th pre-clinical study and is advancing the proprietary psychedelic molecules CYB003 and CYB004 into Investigational New Drug (IND)-enabling studies. The studies utilized Cybin's technology and were executed rapidly through collaboration with partners. The company has initiated an API manufacturing contract and aims to address serious psychiatric conditions with these new candidates. Cybin boasts a discovery pipeline of over 50 proprietary psychedelic molecules, enhancing its position in the emerging psychedelic therapeutics market.
Cybin, a biotechnology company specializing in psychedelic therapeutics, announced that CEO Doug Drysdale will present a business and pipeline update at the Oppenheimer 31st Annual Healthcare Conference on March 18, 2021, at 11:20 AM Eastern Time. The presentation will also be available via a live webcast for seven days afterward. Cybin is known for its innovative approaches to drug discovery, delivery systems, and psychiatric disorder treatments.
Cybin Inc. (NEO:CYBN, OTCQB:CLXPF), a biotechnology company focused on psychedelic therapeutics, announced that CEO Doug Drysdale will present a business update at the M Vest and Maxim Group 2021 Emerging Growth Virtual Conference on March 17, 2021, at 3:30 PM ET. He will also participate in a panel discussion on psychedelics, which will be webcast live and available for replay for one week. Cybin leverages proprietary drug discovery and delivery systems to develop treatments for psychiatric disorders.
Cybin Inc. has commenced trading on the OTCQB under the symbol ‘CLXPF’ as of March 8, 2021. This move enhances the company's visibility and liquidity, allowing better access to both institutional and retail investors, as highlighted by CEO Doug Drysdale. The OTCQB, recognized by the SEC, offers stricter compliance and quality standards, which could positively impact investor confidence. Cybin continues to trade on the NEO Exchange under the symbol ‘CYBN’ and focuses on developing psychedelic therapeutics for mental health issues.